Robert W. Baird started coverage on shares of Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) in a research note issued to investors on Thursday, Briefing.com reports. The firm set an “outperform” rating and a $50.00 price target on the stock. Robert W. Baird’s price objective points to a potential upside of 47.62% from the company’s current price.
A number of other equities research analysts have also weighed in on SYRE. Wells Fargo & Company upgraded Spyre Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $12.00 to $35.00 in a research report on Friday, March 1st. Stifel Nicolaus upped their price objective on shares of Spyre Therapeutics from $36.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, March 26th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $41.00.
View Our Latest Report on Spyre Therapeutics
Spyre Therapeutics Stock Performance
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last issued its earnings results on Thursday, February 29th. The company reported ($2.28) EPS for the quarter, missing the consensus estimate of ($0.48) by ($1.80). On average, sell-side analysts anticipate that Spyre Therapeutics will post -2.36 earnings per share for the current year.
About Spyre Therapeutics
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Recommended Stories
- Five stocks we like better than Spyre Therapeutics
- What to Know About Investing in Penny Stocks
- Yum! Brands: Can Digital Strength Offset Same-Store Declines?
- What is Insider Trading? What You Can Learn from Insider Trading
- Wall Street Believes in First Solar Stock’s Bull Cycle
- 3 Monster Growth Stocks to Buy Now
- AMD is Down 35%. Now is the Time to Buy the Dip
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.